Loading clinical trials...
Loading clinical trials...
Randomized, Placebo-controlled, Phase 3 Study to Compare Efficacy and Safety of Masitinib at 6 mg/kg/Day to Placebo in Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap
Conditions
Interventions
Masitinib
Placebo
+1 more
Locations
24
United States
UC Davis Health System , Department of Dermatology
Sacramento, California, United States
MD Anderson Cancer Centre
Houston, Texas, United States
CHU d'Amiens
Amiens, France
Hôpital Avicenne
Bobigny, France
CHU de Brest
Brest, France
CHU de Caen
Caen, France
Start Date
December 1, 2008
Primary Completion Date
November 1, 2015
Completion Date
November 1, 2015
Last Updated
December 3, 2019
Lead Sponsor
AB Science
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions